Proton beam therapy – re-review
HTCC final approval of coverage decision

(From page 7 of decision aid)

Next step: Proposed findings and decision and public comment

At the next public meeting the committee will review the proposed findings and decision and consider any public comments as appropriate prior to a vote for final adoption of the determination.

☐ 1) Based on public comment was evidence overlooked in the process that should be considered?

☐ 2) Does the proposed findings and decision document clearly convey the intended coverage determination based on review and consideration of the evidence?

Next step: Final determination

Following review of the proposed findings and decision document and public comments:

Final vote

☐ Does the committee approve the Findings and Decisions document with any changes noted in discussion?

If yes, the process is concluded.

If no, or unclear outcome (i.e., tie), chair will lead discussion to determine next steps.
Number and coverage topic:

20190517A – Proton beam therapy

HTCC coverage determination:

Proton beam therapy is a **covered benefit** for children/adolescents less than 21 years old.

Proton Beam Therapy is a **covered benefit with conditions** for individuals 21 years old and older, consistent with the criteria identified in the reimbursement determination.

HTCC reimbursement determination:

Limitations of coverage:

For individuals 21 years old and older proton beam therapy is a covered benefit with conditions for the following cancers:

- Esophageal
- Head/ neck
- Skull-based
- Primary hepatocellular carcinoma
- Brain/ spinal
- Ocular
- Other cancers where all other treatment options are contraindicated after review by a multidisciplinary tumor board.

Non-covered indicators:

Proton beam therapy is **not covered** for all other conditions.

Agency contact information:

<table>
<thead>
<tr>
<th>Agency</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor and Industries</td>
<td>1-800-547-8367</td>
</tr>
<tr>
<td>Public Employees Health Plan</td>
<td>1-800-200-1004</td>
</tr>
<tr>
<td>Washington State Medicaid</td>
<td>1-800-562-3022</td>
</tr>
</tbody>
</table>
HTCC coverage vote and formal action:

**Committee decision**

Based on the deliberations on key health outcomes, the committee decided that it had the most complete information: a comprehensive and current evidence report, public comments, and state agency utilization information. The committee concluded that the current evidence on proton beam therapy demonstrates that there is sufficient evidence to cover or cover with conditions. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable. Based on these findings, the committee voted to cover with conditions or cover proton beam therapy based on age. For pediatric patients (less than 21 years of age) the technology is covered. For adults (21 years of age and older) the technology is covered with conditions.

Based on these findings, the committee voted to cover Proton beam therapy with conditions.

<table>
<thead>
<tr>
<th></th>
<th>Not covered</th>
<th>Covered under certain conditions</th>
<th>Covered unconditionally</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children/ adolescents less than 21 years old</td>
<td>0</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Individuals 21 years old and older</td>
<td>0</td>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

**Discussion**

The committee reviewed and discussed the available studies for use of proton beam therapy. Details of study design, inclusion criteria, outcomes and other factors affecting study quality were discussed. A majority of committee members found the evidence sufficient to determine that use of proton beam therapy is safer and more efficacious than comparators. The committee found that cost-effectiveness was unproven.

**Limitations**

For individuals 21 years old and older proton beam therapy is a **covered with conditions** for the following cancers:
- Esophageal
- Head/ neck
- Skull-based
- Primary hepatocellular carcinoma
- Brain/ spinal
- Ocular
- Other cancers where all other treatment options are contraindicated after review by a multidisciplinary tumor board.

**Non-covered indicators**

Proton beam therapy is not covered for all other conditions.
**Action**

The committee checked for availability of a Centers for Medicare and Medicaid Services (CMS) national coverage decision (NCD). There is no Medicare NCD for proton beam therapy.

The committee discussed clinical guidelines identified for proton beam therapy from the following organizations:

- American Imaging Management (AIM) (2018)
- American Society of Clinical Oncology (ASCO) (2018)
- American Society for Radiation Oncology (ASTRO) (2018)
- National Cancer Care Network (NCCN) (2018)

The committee’s determination is consistent with these guidelines.

The committee chair directed HTA staff to prepare a findings and decision document on use of proton beam therapy for public comment, to be followed by consideration for final approval at the next public meeting.

**Health Technology Clinical Committee Authority:**

Washington State’s legislature believes it is important to use a science-based, clinician-centered approach for difficult and important health care benefit decisions. Pursuant to chapter 70.14 RCW, the legislature has directed the Washington State Health Care Authority (HCA), through its Health Technology Assessment (HTA) program, to engage in an evaluation process that gathers and assesses the quality of the latest medical evidence using a scientific research company and that takes public input at all stages.

Pursuant to RCW 70.14.110 a Health Technology Clinical Committee (HTCC) composed of eleven independent health care professionals reviews all the information and renders a decision at an open public meeting. The Washington State HTCC determines how selected health technologies are covered by several state agencies (RCW 70.14.080-140). These technologies may include medical or surgical devices and procedures, medical equipment, and diagnostic tests. HTCC bases its decisions on evidence of the technology’s safety, efficacy, and cost effectiveness. Participating state agencies are required to comply with the decisions of the HTCC. HTCC decisions may be re-reviewed at the determination of the HCA Director.
Key Questions and Background

Proton beam therapy – re-review

Background:

Clinical need and target population
Overall, it’s estimated that 1.7 million new cases of cancer are diagnosed yearly and cancerous conditions are responsible for over half a million deaths per year. Treatment options for cancerous and noncancerous conditions vary depending on the type and stage of cancer and can include radiation therapy, chemotherapy, targeted therapy (e.g. inhibitor drugs), immunotherapy (including monoclonal antibodies) and surgery. In recent years the use of proton beam therapy (PBT) has expanded to include a variety of conditions including a number of cancer types, noncancerous brain tumors and cancerous conditions affecting the central nervous system as well as eyes, lungs, liver, prostate, spine, and pelvis.

Technology of interest
The use of protons for radiotherapy has a history of over 60 years of clinical use. In conventional radiotherapy, photons deliver radiation across tissue depths on the way toward the target tumor and beyond. In contrast, PBT, which is a form of external beam radiotherapy, deposits peak radiation energy more precisely at or around the target followed by sharp decline in energy output to deeper tissues via a phenomenon known as the Bragg peak (Larsson, 1958). Because the proton beam is focused on a specific area, a greater dose of radiation may be delivered to the target neoplasm(s) while mitigating unwanted radiation delivered to surrounding tissue (Levin, 2005). PBT use was initially directed towards conditions where sparing sensitive adjacent normal tissues was considered to be of utmost importance (such as cancerous or noncancerous malformations of the brain stem, eye, or spinal cord) or for many pediatric tumors because of the particular risk of pronounced acute and long-term toxicity in pediatric patients (Thorp, 2010). PBT may be most promising for tumors in close proximity to organs at risk (OAR).

In the past two decades the number of centers offering PBT has increased to over 20, with more planned or under construction, even given the high cost of facility construction and operation. Despite increasing availability of PBT and its potential for precise delivery of radiation therapy, evidence of its effectiveness compared with other forms of therapy and with the emerging techniques, such as intensity modulated radiation therapy (IMRT) is evolving and currently not unclear for some conditions.

Policy context/reason for selection:
This topic was originally reviewed in 2014. It is being re-reviewed in 2018 due to newly available published evidence.
Objectives

The aim of this report is to update the 2014 HTA on proton beam therapy (PBT) by systematically reviewing, critically appraising and analyzing new research evidence on the safety and efficacy of PBT, as a primary or as a salvage therapy (i.e., for recurrent disease or failure of initial therapy), for the treatment of multiple cancer types as well as selected noncancerous conditions in adults and children.

Key questions (from previous report):

1. What is the comparative impact of proton beam therapy (PBT) treatment with curative intent on survival, disease progression, health-related quality of life, and other patient outcomes versus radiation therapy alternatives and other cancer-specific treatment options (e.g., surgery, chemotherapy) for the following conditions:
   a. Cancers
      i. Bone tumors
      ii. Brain, spinal, and paraspinal tumors
      iii. Breast cancer
      iv. Esophageal cancer
      v. Gastrointestinal cancers
      vi. Gynecologic cancers
      vii. Head and neck cancers (including skull base tumors)
      viii. Liver cancer
      ix. Lung cancer
      x. Lymphomas
      xi. Ocular tumors
      xii. Pediatric cancers (e.g., medulloblastoma, retinoblastoma, Ewing’s sarcoma)
      xiii. Prostate cancer
      xiv. Soft tissue sarcomas
      xv. Seminoma
      xvi. Thymoma
      xvii. Other cancers
   b. Noncancerous Conditions
      i. Arteriovenous malformations
      ii. Hemangiomas
      iii. Other benign tumors (e.g., acoustic neuromas, pituitary adenomas)

2. What is the comparative impact of salvage treatment (including treatment for recurrent disease) with proton beam therapy versus major alternatives on survival, disease progression, health-related quality of life, and other patient outcomes versus radiation therapy alternatives and other cancer-specific treatment options (e.g., surgery, chemotherapy) for the condition types listed in key question 1?

3. What are the comparative harms associated with the use of proton beam therapy relative to its major alternatives, including acute (i.e., within the first 90 days after treatment) and late (>90 days) toxicities, systemic effects such as fatigue and erythema, toxicities specific to each cancer type (e.g., bladder/bowel incontinence in prostate cancer, pneumonitis in lung or breast cancer), risks of secondary malignancy, and radiation dose?
4. What is the differential effectiveness and safety of proton beam therapy according to factors such as age, sex, race/ethnicity, disability, presence of comorbidities, tumor characteristics (e.g., tumor volume and location, proliferative status, genetic variation) and treatment protocol (e.g., dose, duration, timing of intervention, use of concomitant therapy)?

5. What is the comparative cost-effectiveness of proton beam therapy in the short- and long-term relative to other types of radiation therapy, radiation therapy alternatives or other cancer-specific treatment options (e.g., surgery, chemotherapy)?

**Final scope:** (based on previous report and consideration of public comment)

**Inclusion and exclusion**

<table>
<thead>
<tr>
<th>Study Component</th>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
</table>
| **Population**  | Adults and children undergoing treatment of primary or recurrent disease to include:  
- Cancers (bone, brain/spinal/paraspinal, breast, esophageal, gastrointestinal, gynecologic, head and neck, liver, lung, ocular, pediatric, and prostate cancers; lymphomas, sarcomas, seminomas, thymomas, other cancers)  
- Noncancerous conditions (arteriovenous malformations, hemangiomas, other benign tumors). | • Conditions not amenable to proton-beam therapy or for which proton beam therapy would be contra-indicated. |
| **Interventions** | • Proton beam therapy (PBT) use as a  
- Curative therapy  
- Primary or monotherapy  
- “Salvage” treatment (e.g. following failure of initial therapy or disease recurrence)  
- “Boost” mechanism to conventional radiation  
- Combination therapy with other treatments (e.g., chemotherapy, surgery). | • Devices or therapies that are not FDA approved or cleared |
| **Comparator**  | • Other radiation therapy alternatives (e.g., intensity-modulated radiation therapy (IMRT), stereotactic radiation techniques, other external beam therapies, and brachytherapy)  
- Other treatment alternatives specific to each condition type treated; may include chemotherapy, immunotherapy, surgical procedures, and other devices (e.g., laser therapy for ocular tumors).  
- Dose/fractionation comparison (will be included for completeness as was done in prior report) but not formally evaluated as evidence | • Technologies or treatments that are not widely available or are no longer routinely used  
• Devices or therapies that are not FDA approved or cleared |
<table>
<thead>
<tr>
<th>Study Component</th>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>Clinical outcomes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Overall survival/disease-free survival</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• All-cause and/or disease-related mortality</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Direct measures of tumor regression, control or recurrence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Incidence of metastases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Secondary or indirect (intermediate) measures</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Patient reported outcomes, including health-related quality of life (HrQoL), based on validated instruments</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Requirements for subsequent therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Other outcomes specific to particular conditions (e.g., visual acuity for ocular tumors, shunt requirements for arteriovenous malformations)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Intermediate measures of tumor recurrence such as biochemical measures</td>
<td></td>
</tr>
<tr>
<td>Safety outcomes</td>
<td>• Treatment-related harms, with a focus on adverse effects requiring medical attention, to include:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>◦ Generalized effects (e.g., fatigue, erythema)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>◦ Localized toxicities specific to each condition (e.g., urinary incontinence in prostate cancer, pulmonary toxicity in lung or breast cancer) to include consideration of:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Early (≤90 days post-treatment)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Late (&gt;90 days post-treatment)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Secondary malignancy risk due to radiation exposure</td>
<td></td>
</tr>
<tr>
<td>Economic outcomes</td>
<td>• Long term and short term comparative cost-effectiveness measures (e.g. ICER)</td>
<td></td>
</tr>
<tr>
<td>Study Design</td>
<td>• Focus will be on highest quality (lowest risk of bias) comparative studies (e.g., randomized controlled trials, comparative cohort studies with concurrent controls) for questions 1-4.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Case series will be considered but will not be the primary focus of evaluation for each key question.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Case series in children with &lt;10 patients will be considered if no comparative studies are available.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Case series designed specifically to evaluate safety may be included</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dosimetry and planning studies may be included for context. To the extent that they specifically answer the key questions, information will be included as part of the evidence base.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Simulation studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Studies of low quality (high risk of bias)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Comparative studies with fewer than 10 per treatment arm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Case reports</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Case series in adults with &lt;30 patients; Case series of ≥ 10 patients may be considered for very rare conditions.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Studies comparing modes of therapy; dose comparisons may be included for completeness/context per previous report</td>
<td></td>
</tr>
</tbody>
</table>

**Final**
<table>
<thead>
<tr>
<th>Study Component</th>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
</table>
| Publication     | • Studies published in English in peer reviewed journals, technology assessments or publically available FDA reports  
• Studies published subsequent to the 2014 report (previous report search date through February 2014)  
• For question 5, comparative, full formal economic analyses (e.g., cost-effectiveness, cost-utility studies) published in English in a peer reviewed journal | • Abstracts, editorials, letters  
• Duplicate publications of the same study that do not report different outcomes or follow-up times  
• Single reports from multicenter trials  
• White papers  
• Narrative reviews  
• Articles identified as preliminary reports when full results are published in later versions  
• Incomplete economic evaluations such as costing studies |

**Figure 1. Analytic framework**

![Analytic Framework Diagram]

- **Intervention**: Proton beam therapy
- **Patients with a condition of focus**
  - KQ 4
- **Intermediate Outcomes**: Intermediate or indirect measures of disease recurrence, progression (e.g., biochemical measures)
- **Primary Clinical Outcomes**:
  - Overall and/or disease-free survival
  - All-cause and/or disease-related mortality
  - Direct measures of tumor regression, control or recurrence
  - Incidence of metastases
- **Secondary Outcomes**:
  - Patient-reported outcomes, including quality of life, using validated instruments
  - Requirements for subsequent therapy
  - Condition-specific outcomes
- **Harms or adverse events**
- **Comparative Cost-effectiveness**
- **Subgroups**:
  - Age
  - Sex
  - Race/ethnicity
  - Presence of comorbidities
  - Tumor characteristics
  - Treatment protocol
- **KQ 1, 2**
- **KQ 3, 4**
- **KQ 5**
The Health Technology Assessment (HTA) program received comments in response to the posted Health Technology Clinical Committee (HTCC) draft findings and decision on Proton beam therapy – re-review.

### Timeline

<table>
<thead>
<tr>
<th>Phase</th>
<th>Date</th>
<th>Public Comment Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Technology recommendations published</td>
<td>March 5, 2018</td>
<td></td>
</tr>
<tr>
<td>Public comments</td>
<td>March 5, to 19, 2018</td>
<td>15</td>
</tr>
<tr>
<td>Selected technologies published</td>
<td>March 23, 2018</td>
<td></td>
</tr>
<tr>
<td>Public comments</td>
<td>March 23, to April 23, 2018</td>
<td>32</td>
</tr>
<tr>
<td>Draft key questions published</td>
<td>July 3, 2018</td>
<td></td>
</tr>
<tr>
<td>Public comments</td>
<td>July 4 to 18, 2018</td>
<td>14</td>
</tr>
<tr>
<td>Final key questions published</td>
<td>July 27, 2018</td>
<td></td>
</tr>
<tr>
<td>Draft report published</td>
<td>March 1, 2019</td>
<td></td>
</tr>
<tr>
<td>Public comments</td>
<td>March 1 to April 1, 2019</td>
<td>32</td>
</tr>
<tr>
<td>Final report published</td>
<td>April 18, 2019</td>
<td></td>
</tr>
<tr>
<td>Public meeting</td>
<td>May 17, 2019</td>
<td></td>
</tr>
<tr>
<td>Draft findings &amp; decision published</td>
<td>June 5, 2019</td>
<td></td>
</tr>
<tr>
<td>Public comments</td>
<td>June 5 to 18, 2019</td>
<td>14</td>
</tr>
</tbody>
</table>

**Total** 107

### Overview

<table>
<thead>
<tr>
<th>Category</th>
<th>Comment Period June 5 to 18, 2019</th>
<th>Received After deadline</th>
<th>Cited Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient, relative, and citizen</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Legislator and public official</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Health care professional</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Industry &amp; manufacturer</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Professional society &amp; advocacy organization</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

**Total** 0 2 0
## Comments

<table>
<thead>
<tr>
<th>Respondents</th>
<th>Representing</th>
<th>Cited Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Scott Warick, Executive Director</td>
<td>National Association for Proton Therapy</td>
<td>Yes</td>
</tr>
<tr>
<td>2. Shana Johnson, MD</td>
<td>Clinical Quality - Care Transformation</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>WA – Health Care Authority</td>
<td>Yes</td>
</tr>
</tbody>
</table>
June 25, 2019

Re: Draft Findings and Decision for Proton Beam Therapy

Health Technology Clinical Committee
Washington State Health Care Authority
626 8th Avenue • P.O. Box 45502
Olympia, WA 98504-5502

To Whom It May Concern:

We thank you for the opportunity to submit comments on the Draft Findings and Decision from the Health Technology Clinical Committee (HTCC) for the 2019 Health Technology Assessment Re-Review of Proton Beam Therapy. At the outset, we believe that proton beam therapy should be covered consistent with the evidence based model policies such as the one issued by the National Association for Proton Therapy (See Appendix 1). In addition, in this letter, we are submitting comments regarding the draft findings and decision following the re-review of proton beam therapy.

By way of background, the National Association for Proton Therapy (“NAPT”) is a nonprofit organization whose mission is to work collaboratively to: (i) educate and raise awareness of the clinical benefits of proton therapy among patients, providers, payers, policymakers, and other stakeholders, (ii) ensure patient choice and access to affordable proton therapy, and (iii) encourage cooperative research and innovation to advance the appropriate and cost-effective utilization of proton therapy for certain cancers. Its members – both hospital based and freestanding – are world-renowned cancer centers, a number of whom are National Cancer Institute (NCI) designated comprehensive cancer centers and National Comprehensive Care Network (NCCN)® members, including the Seattle Cancer Care Alliance Proton Therapy Center.

**Pediatric Cancers**

Based on its review of the evidence, the HTCC made a preliminary determination to cover proton beam therapy (PBT) based on age. Specifically, the committee has decided to cover PBT without conditions for patients under 21 years of age. We applaud the committee’s decision for broad coverage for pediatric patients following the review of the evidence presented. Based on our members’ experiences with pediatric patients across the country, the NAPT recommends the following two revisions to the committee’s draft decision:

- Define pediatric patients as 21 years and under, rather than under 21 years of age
- Allow coverage for treatment of predominantly pediatric cancers that occur in young adults such as lymphomas, sarcomas, and cancers of the central nervous system, primarily neoplasms that arise from non-ectodermal tissue such as bone marrow, lymph glands, bone, and muscle
- Permit coverage for young adults with a reoccurrence of a cancer that was originally treated when the patient was 21 years or younger

PBT has been shown to target tumors, spare surrounding normal organs and tissues from radiation exposure, significantly reduce or eliminate both the acute and chronic toxicities from ionizing radiation, and therefore, improve quality of life of patients. Therefore, leading cancer centers believe that PBT is an appropriate treatment option for pediatric cancer patients through age 21 and for young adults.

---

diagnosed with pediatric cancers. As such, we are respectfully requesting that the HTCC revise its findings and decision on coverage for pediatric patients to reflect suggestions noted above.

**COVERED INDICATIONS**

In the discussion of its draft findings and decision, the HTCC preliminarily approved (a) coverage with conditions for ten indications for individuals 21 years and older, (b) coverage unconditionally for nine indications for patients under 21 years old, and (c) coverage with certain conditions for one indication for patients under 21 years old. However, in the draft findings and decision, the HTCC does not specifically outline the indications covered (or covered with certain conditions). The findings only list the following seven indications:

- Esophageal;
- Head and neck;
- Skull-based;
- Primary hepatocellular carcinoma;
- Brain / spinal;
- Ocular; and,
- Other cancers where all other treatment options are contraindicated following review by a multi-disciplinary tumor board.

We request that the HTCC clarify the number of indications and the specific indications for which it has preliminarily approved for coverage or coverage under certain conditions.

* * * * *

We appreciate your consideration of our feedback on the Draft Findings and Decision by the Health Technology Clinical Committee based on the 2019 Health Technology Assessment Re-Review of Proton Beam Therapy. Should you have any questions, please do not hesitate to contact Scott Warwick, NAPT Executive Director, at swarwick@proton-therapy.org.

Respectfully submitted,

Scott Warwick
Executive Director
Primary Brain or spinal cord malignancy or ANY (including metastatic) brain or spinal cord malignancy/tumor